This dissertation consists of two unrelated chapters. The first chapter asks two questions related to the availability of drugs in India. First, what are the characteristics of the firms that initially enter the market with new drugs in India, and which firms follow? Second, to what extent does the U.S. generic market impact the entry decisions of firms in the Indian pharmaceutical market? A discrete-time hazard model estimates the probability that a firm launches a new drug into the Indian market between 1991 and 2004. The results suggest that large, Indian pharmaceutical manufacturers are more likely to launch a new drug than small, domestic manufactures or foreign-based firms. In addition, large domestic manufacturers are more likely to launch a drug in India if that drug will lose patent protection in the U.S. within three years.I. Introduction According to the popular press, the aquot;Lipitor Waraquot; began in June, 2006, although the combatants began laying the groundwork years earlier. The precipitating event was the loss of patent protection for the cholesterol fighting druganbsp;...
|Title||:||Essays on the Indian and U.S. Pharmaceutical Industry|
|Publisher||:||ProQuest - 2008|